The Bull Rankings scorecard — our quality-growth score is 86.3 / 100, built from three pillars scored 0–100: Quality 87, Growth 91, Value 81 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 4% a year, holding there through year ten — a gauge of how much optimism is already in the stock.
The thesis
ADMA Biologics sits at the intersection of a high‑margin specialty biopharma and a disciplined capital‑allocation strategy. Its P/E of 14.8 places it well below the healthcare median, and the PEG of 0.8 signals that the market is already pricing in a modest growth premium. Yet the company’s free‑cash‑flow of $116 m and profit margin of 33 % show that it is not merely a cash‑burning growth play. Our model’s quality‑growth score of 86.3 is anchored by a Growth pillar of 91—the highest of the three—while the Value pillar of 81 confirms that the stock is still on the cheap side of its peers. In short, the thesis is that ADMA’s robust cash generation, coupled with a disciplined share‑repurchase program, creates a durable moat that justifies a modest upside from today’s price.
What the business actually is
ADMA’s revenue engine is built around plasma‑derived biologics. The company operates two segments: ADMA BioManufacturing, which develops and produces the biologics, and Plasma Collection Centers, which harvest the raw material. Its flagship products—BIVIGAM and ASCENIV, both intravenous immune globulins (IVIG) for primary humoral immunodeficiency, and Nabi‑HB, a human polyclonal antibody for acute hepatitis B exposure—drive the bulk of sales. These products serve a niche but growing patient population, and the company’s manufacturing footprint gives it a competitive edge in supply chain control.
Why it can (or can't) keep compounding
The durability case hinges on high operating leverage and capital efficiency. With a profit margin of 33 % and a ROE of 41.9 %, ADMA turns cash into equity returns at a pace that rivals the best in biotech. The debt‑to‑equity of 0.5 keeps leverage low, allowing the firm to fund growth without diluting shareholders. The “Buying back stock” signal in our model underscores a commitment to returning excess cash to investors, tightening the capital structure and boosting earnings per share. Competing firms face significant barriers: plasma collection requires specialized facilities, and the regulatory pathway for IVIG products is stringent. These hurdles make rapid imitation difficult, preserving ADMA’s market share.
The valuation question
The market’s current valuation implies a free‑cash‑flow growth of about 4 % per year in the first year, tapering to 4 % by year ten. This starting rate is lower than the trailing revenue growth of 19.6 %, meaning the price already discounts the recent acceleration. In other words, the stock is priced with a degree of pessimism relative to the business’s recent performance. The P/E of 14.8—cheaper than most healthcare peers—further suggests that the market has not fully absorbed the upside potential of a 19.6 % revenue growth rate. Thus, the valuation view is that the current price is already conservative, leaving room for upside if the company sustains its growth trajectory.
The bear case
The most compelling skeptic points to the weakest pillar—Value at 81. While still on the cheap side, a Value score that is the lowest of the three indicates that the market may be wary of future growth sustainability. If the company’s free‑cash‑flow growth fails to keep pace with the 19.6 % revenue growth, the implied 4 % DCF assumption will become untenable, eroding the price cushion. A concrete trigger would be a decline in profit margin below 30 %, which would signal cost pressures or pricing power erosion.
What would change our mind
- Profit margin falling below 30 % would erode the high‑margin moat and weaken the durable returns narrative.
- Free‑cash‑flow growth dropping below 4 % for two consecutive quarters would invalidate the reverse‑DCF assumption, prompting a re‑evaluation of the price.
- A significant drop in the Value pillar below 70—indicating that the stock is no longer cheap relative to peers—would shift the balance toward a more cautious stance.
If any of these thresholds were breached, the current thesis would need to be revisited.